Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Declines By 27.8%

Alpha Tau Medical Ltd. (NASDAQ:DRTS) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 88,100 shares, a decrease of 27.8% from the March 15th total of 122,000 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 89,800 shares, the short-interest ratio is currently 1.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Alpha Tau Medical in a research report on Monday, March 17th.

Institutional Investors Weigh In On Alpha Tau Medical

Several institutional investors have recently made changes to their positions in DRTS. Renaissance Technologies LLC grew its position in shares of Alpha Tau Medical by 188.7% in the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock valued at $127,000 after purchasing an additional 26,800 shares in the last quarter. Northern Trust Corp boosted its stake in Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock worth $151,000 after purchasing an additional 25,770 shares during the period. Finally, Levin Capital Strategies L.P. grew its holdings in Alpha Tau Medical by 2.3% during the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock valued at $975,000 after buying an additional 7,189 shares in the last quarter. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Stock Up 1.6 %

NASDAQ DRTS opened at $2.57 on Friday. The company has a market cap of $180.88 million, a PE ratio of -5.98 and a beta of 0.93. Alpha Tau Medical has a 52 week low of $1.75 and a 52 week high of $4.39. The firm’s 50-day simple moving average is $2.70 and its two-hundred day simple moving average is $2.82.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). As a group, equities research analysts anticipate that Alpha Tau Medical will post -0.45 EPS for the current year.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.